Reaction profile

The FDA adverse-event record for pancreatic tumour nos

Name: Pancreatic tumour NOS - FDA Animal Adverse Reaction
Creator: PlainBreed
License: https://open.fda.gov/license/

17 FDA reports name pancreatic tumour nos, a lower-volume reaction in the CVM extract (VeDDRA 2943). Plate stamps and neighbourhood peers follow.

#2252 of 2,481
by report volume (all reactions): 17
reports citing this reaction: 70.6%
death-coded share: Dog
most-affected species

Compiled by PlainBreed

Verify with FDA CVM →

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Pancreatic tumour NOS has 17 reports now versus 17 in that prior snapshot: 0 the same number of (0.0%).

Report change: +0
Death-coded reports: +0
Death-coded share: +0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Pancreatic tumour NOS changes

FDA AER · VeDDRA plate

Code 2943 VOL-TRACE

VOL-TRACE · DEATH-HOT · BOTTOM-DECILE · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL

VOL-TRACE 17 reports
DEATH-HOT 70.6%
BOTTOM-DECILE #2252/2481
PHOTO-FINISH Anoestrus
SPECIES-DOG Dog · 11
DRUG-LEAD Maropitant Citrate · 6
DESK-WIDE 14 breeds
BOOK-FULL 8/8 fields

Nearest volume peer: Anoestrus (±0 reports)

Upper-third death-coded share drives the outcome stamps on this plate; volume band, corpus rank, and co-report peers follow. Not a clinical diagnosis.

Lower-volume neighbourhood around Pancreatic tumour NOS

Lower-third volume poles plus nearest peers, not a full reaction corpus board reprint.

FDA AER report volume · neighbourhood around Pancreatic tumour NOS

Pancreatic tumour NOS: high death-coded share in the FDA AER plate

Signature read: Pancreatic tumour NOS's 70.6% death-coded share is among the highest in the openFDA reaction corpus. Report volume is lower-third scale: 17 named reports in the openFDA extract. Death-coded share is upper-third: 12 of 17 reports (70.6% of named reports). Nearest volume peer: Anoestrus (±0 reports). Lead species Dog (11). Lead co-reported drug Maropitant Citrate (6).

Read these counts as reporting volume, not risk: per our methodology, A high death-coded share in FDA filings does not prove causation; co-reporting is voluntary temporal association only. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.

Species Most Affected

Dog 11

Cat 6

Breeds Most Affected

Domestic Shorthair 4

Corgi - Welsh Pembroke 1

Poodle - Toy 1

Shih Tzu 1

Chihuahua 1

Crossbred Canine/dog 1

Siberian Husky 1

Terrier - West Highland White 1

Maine Coon 1

Catahoula Leopard Dog 1

Associated Drugs

Maropitant Citrate 6

Gabapentin 3

Bedinvetmab 3

Dexmedetomidine Hydrochloride 2

Ampicillin 2

Benadryl 2

Moxidectin 2

Ivermectin + Pyrantel As Pamoate Salt 2

Frunevetmab 2

Carprofen 2

Bexagliflozin 2

Dexamethasone + Neomycin Sulfate + Thiabendazole 1

Recombinant E. Coli Bl21;Recombinant E. Coli Ecl19 1

Atipamezole Hydrochloride 1

Nobivac Leptospirosis Vaccine 1

Vitamin K 1

Denamarin 1

Pepsin 1

Fresh Frozen Plasma 1

Unspecified Fluids 1

What to do with this reaction

Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
Browse the full reaction directory to compare report counts across reaction types. All reactions

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Pancreatic tumour NOS (#2252 of 2,481 by report volume); death-coded 70.6%. PlainBreed reaction plate · death-coded share stamp 70.6% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →